ORYZON continues to strengthen its patent portfolio for vafidemstat

Oryzon Genomics S.A., (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA3071804 and IL272092, titled “Methods of treating behavior alterations”, related to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders.

The allowed claims cover the use of vafidemstat for the treatment of aggression and social withdrawal – two symptoms associated with several CNS disorders. Oryzon has recently submitted a clinical trial protocol to the U.S. Food and Drug Administration (FDA) for a Phase III trial to evaluate vafidemstat in the treatment of aggression in borderline personality disorder (BPD). The company is also planning to conduct a Phase II trial in aggression in Austism Spectrum Disorder (ASD) patients, and a Phase II trial is already ongoing in schizophrenia.

A “Decision to grant” is an official communication from a national patent office indicating that a patent application has met all requirements for issuance as a patent. Once formally granted, the Canadian and Israeli patents will remain in force until at least 2038, excluding any potential patent term extensions, which could provide additional years of protection. These allowances add to an expanding global patent portfolio for vafidemstat. Corresponding patents have already been granted/allowed in Europe, Australia, Hong Kong, South Korea, Malaysia, the Philippines, and Russia, and additional applications are pending in other countries.

“These patent allowances in Canada and Israel complement the robust portfolio we’ve already secured for vafidemstat, further strengthening our global IP position and supporting its commercial potential across multiple CNS indications”, said Neus Virgili, Oryzon’s Chief IP Officer.

In addition to this patent family, Oryzon holds other patents covering the use of vafidemstat in CNS disorders, including a patent family directed to the treatment of BPD or non-aggressive symptoms of BPD, with granted or allowed patents in Europe, Japan, Mexico, Russia, Singapore and South Africa. These patents are expected to remain in force until at least 2040, not including any potential patent term extensions.